Advaxis (NASDAQ:ADXS) and AstraZeneca's (NYSE:AZN) MedImmune establish a clinical trial collaboration to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' cancer immunotherapy vaccine ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.
MEDI4736 is designed to counter a tumor's immune-evading tactics by blocking a signal that helps the tumor avoid detection. ADXS-HPV enhances the ability of immune cells to fight the tumor.
The Phase 1 trial will establish the recommended dose regimen while the Phase 2 trial will assess the safety and efficacy of the combination. Advaxis will fund and conduct the trials.
Under the terms of the collaboration, MedImmune has the first right of negotiation for future development of the combination.